Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Phase II Study of DS-5141b (renadirsen) in Duchenne Muscular Dystrophy
jRCT2080225225Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of renadirsen in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Jun 2020; status: completed.
02
Drugs
renadirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2080225225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225225.